Welcome to our dedicated page for In8Bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on In8Bio stock.
Overview
In8Bio, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of innovative gamma-delta T cell immunotherapies for cancer treatment. Utilizing state-of-the-art approaches such as allogeneic, autologous, and genetically modified T cells, the company is at the forefront of applying advanced immunology in the fight against both solid and hematologic malignancies. By leveraging its robust DeltEx platform, In8Bio is pioneering the integration of cell-based therapies into standard clinical protocols, a subject of high relevance in the fields of oncology and immunotherapy.
Clinical Programs and Technological Innovation
The company is deeply engaged in multiple clinical programs that advance its gamma-delta T cell product candidates into various stages of clinical investigation. Its innovative approach harnesses the unique ability of gamma-delta T cells to recognize and destroy cancer cells while differentiating between healthy and diseased tissues. The immunotherapies developed by In8Bio are designed to overcome current challenges in cancer treatment by demonstrating resilience in the presence of conventional modalities such as chemotherapy. This novel methodology indicates a significant step forward in addressing persistent gaps in progression-free survival for patients afflicted with difficult-to-treat cancers.
Pipeline and Portfolio
In8Bio maintains a diverse portfolio of cell therapy candidates that target both solid tumors, such as aggressive brain cancers, and liquid tumors, including high-risk hematologic malignancies. The company emphasizes the potential of its genetically modified gamma-delta T cells which are engineered to be chemotherapy-resistant, thereby enabling their effective use in combination with standard-of-care treatments. Its strategic portfolio reflects a deliberate focus on creating therapies that provide robust antitumor activity with a favorable safety profile, which is crucial in clinical settings.
Market Position and Competitive Landscape
Operating within a competitive and dynamic segment of the biotechnology and oncology markets, In8Bio distinguishes itself by being one of the first companies to translate genetically modified gamma-delta T cell therapy into clinical studies. The company’s efforts to integrate advanced cell therapy with conventional cancer management protocols underscore its role as a pioneer in the immunotherapy space. Its scientific and clinical strategies are rooted in extensive research, aiming to expand treatment options for patients with unmet medical needs while setting a benchmark for future research in cell-based therapies.
Research and Development Focus
The core of In8Bio’s business model lies in its commitment to rigorous research and clinical validation. The company employs a systematic approach to clinical investigation, ensuring that its product candidates are evaluated through well-designed studies. This commitment to science and robust clinical trial methodologies not only enhances the credibility of its findings but also contributes to the broader scientific understanding of gamma-delta T cell functions in oncology. The integration of innovative technologies with traditional treatment regimens speaks to the company’s strategy of enhancing therapeutic durability and safety.
Operational Excellence and Strategic Vision
In8Bio is characterized by its deep commitment to scientific excellence and operational transparency. Its research pipeline is supported by meticulous clinical studies that investigate both short-term efficacy and long-term safety profiles of its cell therapies. By positioning its programs at the interface of immunology and oncology, the company provides a pertinent example of how novel biotechnology can offer alternative options for cancer patients. This blend of advanced immunotherapeutic strategies and rigorous clinical science reinforces In8Bio’s reputation as a credible and knowledgeable entity in the biopharmaceutical landscape.
Investor Insights and Frequently Asked Questions
Investors and industry researchers looking into In8Bio will find that the company’s emphasis on gamma-delta T cell therapies offers a unique intersection of cellular immunotherapy and targeted cancer treatments. The detailed clinical programs, alongside strategic R&D initiatives, provide ample context on the company’s approach to addressing unmet needs in oncology. By maintaining a balanced perspective on both the promise and challenges inherent in advanced cell therapies, In8Bio continues to contribute to the evolution of cancer treatment paradigms with ongoing scientific rigor and clinical evaluation.
IN8bio, a clinical-stage biopharmaceutical company, announced its presentations for upcoming April conferences. At the AACR Annual Meeting 2022 in New Orleans, Dr. Lawrence Lamb will discuss γδ T cell-based therapy for gliomas on April 11, and Dr. Lei Ding will address drug-resistant immunotherapy on April 13. Additionally, CEO William Ho will participate in a panel at the BIO Alabama Annual Conference 2022 on April 25.
IN8bio specializes in developing gamma-delta T cell therapies for tumors and is currently running Phase 1 trials for INB-200 and INB-100.
IN8bio, Inc. (Nasdaq: INAB) shared promising results from its ongoing Phase 1 trial of INB-100 for treating patients with high-risk acute myeloid leukemia (AML). All three patients treated showed durable remissions lasting 23.3, 21.0, and 9.3 months post-bone marrow transplant (BMT). The immune systems of patients were effectively reconstituted at six months, with no serious treatment-related adverse events reported. This update was presented at the European Society for Blood and Marrow Transplantation (EBMT) 48th Annual Meeting, indicating potential for further clinical advancements.
IN8bio reported promising clinical results for INB-200 and INB-100, showing a well-tolerated safety profile and extended progression-free survival in glioblastoma and leukemia patients, respectively. The company raised $40 million through an IPO to fund development of its gamma-delta T cell therapies. Financially, it ended 2021 with $37 million in cash, up from $18 million in 2020. However, it also faced a net loss of $14.7 million for the year. As the company continues to advance its clinical programs, it plans to file an IND for INB-400 and present at several upcoming scientific conferences.
IN8bio, Inc. (Nasdaq: INAB) announced its participation in several upcoming virtual and hybrid conferences in March 2022. Key events include the European Society for Medical Oncology Congress on March 7-8, featuring a presentation on engineered γδ T-cells, and the Cowen 42nd Annual Health Care Conference on March 7, where CEO William Ho will discuss the company overview. Additional presentations will take place at the Oppenheimer Healthcare Conference and the European Society for Blood and Marrow Transplantation meeting.
IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company focused on gamma-delta T cell therapies, announced executive presentations at two upcoming events. The BIO CEO & Investor Conference will take place from February 14-17, 2022, featuring CEO Will Ho. Additionally, at the Next Generation CAR-TCR Summit in London on February 22-24, 2022, CSO Dr. Lawrence Lamb and COO Dr. Kate Rochlin will present relevant research on CAR-T cell therapies. IN8bio is advancing clinical trials for its lead products targeting glioblastoma and leukemia.
IN8bio (Nasdaq: INAB) announced that CEO William Ho will present at four virtual investor conferences in January 2022. Key events include:
- H.C. Wainwright & Co. BioConnect Conference: January 10-13
- Solebury Trout Management Access: January 10-13 & 18-20
- Biotech Showcase: January 10, 11:00 a.m. EST
- B. Riley Virtual Oncology Conference: January 27, 11:00 a.m. EST
IN8bio focuses on developing gamma-delta T cell therapies for cancers.
IN8bio, Inc. (Nasdaq: INAB) announced a promising update on INB-200, the first genetically modified gamma-delta T cell therapy in clinical trials for glioblastoma multiforme (GBM). Currently in a Phase 1 trial, Cohort 1 has completed dosing with no dose limiting toxicities or serious adverse events, while Cohort 2 is actively enrolling patients. Notably, all treated patients exceeded expected progression-free survival intervals, demonstrating a potential improvement in overall survival. The trial aims to assess safety, tolerability, and efficacy of the therapy combined with standard chemotherapy.
IN8bio has announced encouraging early results from its ongoing Phase 1 trial of INB-100, a gamma-delta T cell therapy for patients with acute myeloid leukemia (AML). Three patients have received treatment, all of whom remain in remission, with two achieving durable responses lasting over 1.5 years. The therapy demonstrated a manageable safety profile, with no significant adverse events reported. This trial aims to explore the efficacy of this novel treatment for patients undergoing haploidentical stem cell transplants, where relapse rates can be high.
IN8bio, Inc. (Nasdaq: INAB) has announced the promotion of Kate Rochlin, Ph.D., to Chief Operating Officer, effective immediately. Dr. Rochlin, who has been with IN8bio since August 2020, previously served as Vice President, Operations and Innovation. She will oversee multiple operational functions and will continue to lead early innovation programs. The company is advancing its gamma-delta T cell therapies aimed at treating solid and liquid tumors, utilizing its proprietary DeltEx platform. IN8bio is conducting two Phase 1 clinical trials for its lead product candidates.
IN8bio, Inc. has appointed Trishna Goswami, M.D. as Chief Medical Officer, effective immediately. Dr. Goswami brings over a decade of experience in immuno-oncology drug development, having worked with notable companies such as Gilead and AstraZeneca. Her expertise includes clinical development for both solid and hematologic tumors, making her a significant addition to IN8bio's leadership team. The company focuses on advancing gamma-delta T cell therapies using its DeltEx platform to improve cancer treatment outcomes. This appointment aligns with IN8bio's goal of progressing multiple therapeutic candidates through clinical development.
FAQ
What is the current stock price of In8Bio (INAB)?
What is the market cap of In8Bio (INAB)?
What is the primary focus of In8Bio, Inc.?
How does In8Bio approach cancer treatment differently?
Which types of cancers does In8Bio target?
What makes the company’s technology innovative?
How does In8Bio ensure the safety of its therapies?
In what stage of development is In8Bio’s therapy pipeline?
How does In8Bio differentiate itself from other biopharmaceutical companies?
What benefits do gamma-delta T cells offer in cancer treatment?
